Orzeyful is an oral orexin receptor 2 (OX2R) agonist designed to address the deficiency of orexin, a brain chemical responsible for regulating wakefulness and sleep.

USA – Japanese drugmaker Takeda has commercially launched Orzeyful (oveporexton) in the US following its August 2026 approval by the Food and Drug Administration (FDA), expanding treatment options for adults living with narcolepsy type 1.
Orzeyful is an oral orexin receptor 2 (OX2R) agonist designed to address the deficiency of orexin, a brain chemical responsible for regulating wakefulness and sleep.
Following FDA approval, the medicine received a Schedule IV controlled substance classification, which governs its prescription and distribution in the US.
Takeda has appointed Accredo Specialty Pharmacy, part of Evernorth Health Services, to manage nationwide distribution.
Licensed healthcare practitioners can prescribe the treatment, while the company is providing patient support programmes to help eligible adults initiate therapy and navigate insurance coverage.
Takeda’s US business unit president, Rhonda Pacheco, said the launch represented an important milestone in the company’s efforts to develop treatments that address unmet patient needs.
She noted that the company would also focus on supporting patients and improving access to the medicine following its introduction.
Targeting orexin deficiency
Narcolepsy type 1 is a chronic neurological disorder associated with the loss of orexin-producing neurons in the brain.
The condition causes excessive daytime sleepiness, disrupted nighttime sleep, cognitive difficulties and cataplexy, characterised by sudden episodes of muscle weakness or loss of muscle tone.
Orzeyful works by selectively activating OX2R pathways to restore orexin signalling.
This mechanism is intended to improve daytime wakefulness and reduce abnormal rapid eye movement (REM) sleep-related symptoms.
Clinical evaluations identified insomnia, excessive saliva production, increased urinary urgency and urinary frequency among the most frequently reported adverse effects.
Beyond the US, regulatory authorities in China and Japan have also approved Orzeyful for adults with narcolepsy type 1, giving Takeda access to multiple major pharmaceutical markets.
Expanding orexin-focused pipeline
Orzeyful is the lead asset in Takeda’s broader strategy to develop medicines targeting orexin pathways.
The company is advancing other investigational oral orexin agonists, including TAK-360, which is being evaluated for idiopathic hypersomnia, narcolepsy type 1 and narcolepsy type 2, as well as TAK-495.
Takeda is also developing digital tools and biomarker-based diagnostic solutions to support earlier identification and differentiation of narcolepsy type 1.
The launch places Takeda in a competitive US narcolepsy market where Jazz Pharmaceuticals has established a strong presence through its oxybate-based treatments, including Xywav and Xyrem.
The introduction of an orexin receptor agonist adds a different therapeutic mechanism to the treatment landscape and creates opportunities for competition around clinical outcomes, patient access and long-term disease management.
Be the first to leave a comment